FDA staff doubts about Jetrea drop ThromboGenics 19%
This article was originally published in Scrip
Executive Summary
The staff of the USFDA has raised potentially serious problems with the application by Belgian biotech ThromboGenics for marketing approval for ocriplasmin. The safety part of the briefing paper written ahead of the 26 July ophthalmic advisory board has pointed to potential drug-related safety issues with the drug ThromboGenics wants to brand Jetrea